Physician profile
Mark A Perini
NPI 1538185574
$3,260.72
in general payments reported to CMS, 2019-2025
42 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $355 · 2021: $173 · 2022: $384 · 2023: $724 · 2024: $371 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.24 |
| Education | $205.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.75 | 2019-2025 | |
| Abbott Laboratories | $233.45 | 2021-2023 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $205.87 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $178.47 | 2019 | |
| Pfizer INC. | $171.06 | 2019-2025 | |
| Radius Health, INC. | $169.50 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $166.74 | 2019-2024 | Shingrix |
| Lilly USA, LLC | $154.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $108.45 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $106.81 | 2019-2023 | |
| Astellas Pharma US INC | $98.78 | 2019-2023 | Veozah |
| Amgen INC. | $95.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $88.58 | 2019-2022 | |
| Novo Nordisk INC | $79.13 | 2019-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $70.94 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Perini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.